Company: DNLI
Filing Date: 2025-05-06
Form Type: 10-Q
Source: 0001714899-25-000105
Chunk: 106

Company: Denali Therapeutics Inc.
Filing Date: 2025-05-06
Form: 10-Q
Item: Part I, Item 1
Chunk 106
---
 2 inputs as discussed in Note 2, "Fair Value Measurements". The amortized cost, gross unrealized holding gains or losses, and fair value of the Company’s marketable securities by major security type at each balance sheet date are summarized in the tables below (in thousands):March 31, 2025Amortized CostUnrealized Holding GainsUnrealized Holding LossesAggregate Fair ValueShort-term marketable securities:U.S. government treasuries$719,287 $1,802 $(24)$721,065 Corporate debt securities39,766 148 — 39,914 Total short-term marketable securities759,053 1,950 (24)760,979 Long-term marketable securities:U.S. government treasuries216,057 413 (11)216,459 Corporate debt securities19,324 61 — 19,385 Total long-term marketable securities235,381 474 (11)235,844 Total$994,434 $2,424 $(35)$996,823 December 31, 2024Amortized CostUnrealized Holding GainsUnrealized Holding LossesAggregate Fair ValueShort-term marketable securities:U.S. government treasuries$627,809 $1,618 $(27)$629,400 Corporate debt securities21,337 62 — 21,399 Commercial paper6,572 — — 6,572 Total short-term marketable securities655,718 1680 (27)657,371 Long-term marketable securities:U.S. government treasuries334,300 788 (196)334,892 Corporate debt securities24,354 127 0 24,481 Total long-term marketable securities358,654 915 (196)359,373 Total$1,014,372 $2,595 $(223)$1,016,744  As of March 31, 2025 and December 31, 2024, some of the Company's marketable securities were in an unrealized loss position. The Company has not recognized an allowance for credit losses as of March 31, 2025 or December 31, 2024. The Company determined that it had the ability and intent to hold all marketable securities that have been in a continuous loss position until maturity or recovery. Further, a majority of these market